MET exon 14 skipping

Approved therapies

Approvals in the United States (FDA) and the European Union (EMA), one row per drug, regimen and tumour type. Where we have them, the pivotal trial's results and side effects are shown under each therapy, from the official label. Results from different trials are not directly comparable: patients, earlier treatments and comparators differ.

Companion diagnostic tests

Tests the FDA has approved to select patients for a specific therapy. Other validated tests are often used in practice, especially in Europe.

Drugs in active trials

Targeted drugs, antibody-drug conjugates and immunotherapies in active trials on this page, approved ones first, then by the furthest phase reached. Chemotherapy and supportive medicines are left out. "Not yet classified" means an early drug known only by its code.

25 of 26 drugs shown

Show all 26 drugs

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months: the date the main results are due to be collected, according to the sponsor. Results are usually published months later, and these dates often slip.

Companies

Industry sponsors leading active trials, by number of trials. Each square is one trial, shaded by phase.

1. AstraZeneca 2
2. Beijing Pearl Biotechnology 1
3. Daiichi Sankyo 1
4. ImmunityBio 1
5. Abion 1
6. Apollomics 1
7. Lantern Pharma 1
8. Merck KGaA 1
9. Betta Pharmaceuticals 1
10. Haihe Biopharma 1
11. Pierre Fabre Medicament 1
12. Avistone Biotechnology 1
13. Bristol Myers Squibb 1
14. CSPC 1
15. DeuterOncology 1

Phase 1 Phase 2 Phase 3 Phase 4 No phase

Trials

Matched automatically from registry text, so a few trials may only mention MET exon 14 skipping rather than require it. Check the quoted criterion, and the registry entry before relying on a match.

33 of 66 trials shown

1. DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations

   Recruiting Phase 2/3 Cancer Research UK Started 2024Primary completion 2029-10 NCT06988475

   capmatinib FDA EU

   …sis of a MET-positive malignancy using an analytically next-generation sequencing method (METex14 skipping, MET amplification, MET fusion, or MET activating mutation).

   Solid Tumour, Haematological Malignancy, Malignant Neoplasm, Neoplasms by Histologic Type

2. A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)

   Recruiting Phase 3 Beijing Pearl Biotechnology Started 2023Primary completion 2026-09 NCT05989542

   vebreltinib

   The presence of MET exon 14 jump mutation was confirmed by the NGS test in the central laboratory, and the 'Combined …

   Non-small Cell Lung Cancer

3. Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer

   Not yet recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai Started 2025Primary completion 2027-09 NCT07153770

   vebreltinib

   MET exon 14 skipping mutation (NGS results from tissue or blood sample certified by CLIA or CAP).

   NSCLC, MET Exon 14 Mutation, MET Activating Mutation

4. Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

   Not yet recruiting Phase 2 Fudan University Started 2025Primary completion 2027-09 NCT07156604

   vebreltinib

   NGS gene testing confirmed MET exon 14 skipping mutations (NGS results from tissue or blood samples certified by CLIA or CAP-app…

   NSCLC, Neoadjuvant Therapy

5. Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer

   Not yet recruiting Phase 2 Nanjing First Hospital, Nanjing Medical University Started 2025Primary completion 2026-12 NCT06762327

   ensartinib

   Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer

   Solid Tumors

6. FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

   Recruiting Phase 1/2 Pierre Fabre Medicament Started 2024Primary completion 2030-10 NCT06669117

   VERT-002

   METex14 mutation

   Solid Tumor, MET Alteration

7. PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer

   Active, not recruiting Phase 1/2 M.D. Anderson Cancer Center Started 2024Primary completion 2027-12 NCT06083857

   amivantamabtepotinib FDA EU

   NSCLC which harbors MET Exon 14 skipping alterations detected in the tissue or ctDNA (safety cohort and cohort A \[MET ex…

   Non-small Cell Lung Cancer

8. Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

   Recruiting Phase 2 SWOG Cancer Research Network Started 2024Primary completion 2028-05 NCT06031688

   ramucirumabtepotinib FDA EU

   Participants must have documentation of stage IV or recurrent NSCLC with a MET exon 14 skipping mutation determined by tissue-based or blood-based (circulating tumor DNA \[ctDN…

   Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

9. c-MET Inhibitor in Advanced Solid Tumors With c-MET Gene Aberration

   Recruiting Phase 2 Yonsei University Started 2023Primary completion 2025-12 NCT05882292

   ABN401

   …o performed NGS tests and c-MET alterations confirmed in molecular tumor board \[MTB\]) - exon 14 skipping mutation except for non-small cell lung cancer (NSCLC)

   Neoplasms

10. To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

    Recruiting Phase 2 Abion Started 2023Primary completion 2029-02 NCT05541822

    Vabametkiblazertinib

    For Cohort 1: MET exon 14 skipping suspected by local or central biomarker assessment. \[local testing is accepted …

    Advanced Solid Tumors

11. Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC

    Active, not recruiting Phase 2 AstraZeneca Started 2022Primary completion 2027-01 NCT05374603

    savolitinibdurvalumab

    MET Exon 14 skipping mutation, or MET overexpression (IHC 3+ in ≥70% of tumor cells), or MET amplific…

    Lung Cancer

12. Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

    Recruiting Phase 1/2 Betta Pharmaceuticals Started 2021Primary completion 2028-04 NCT04930432

    MCLA-129

    MET positive is defined as: MET amplification or MET exon 14 skipping mutation.

    Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Colorectal Cancer

13. Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

    Recruiting Phase 1/2 Haihe Biopharma Started 2019Primary completion 2023-10 NCT04270591

    glumetinib

    METex14 skipping mutation who had previously treated by other MET inhibitor(s) or

    Status may be outdated, last updated 2022-08-01C-Met Exon 14 Mutation

14. APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

    Recruiting Phase 2 Apollomics Started 2017Primary completion 2026-03 NCT03175224

    vebreltinib

    …C MET inhibitor naive in first line: Histologically or cytologically confirmed NSCLC with Exon 14 skipping mutations

    Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer

15. Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

    Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2016Primary completion 2022-11 NCT06360575

    crizotinib

    Patient must have MET exon 14 skipping as defined via the MATCH Master Protocol and described or other mutations that d…

    Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm

16. Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

    Active, not recruiting Phase 2 Merck KGaA Started 2016Primary completion 2022-05 NCT02864992

    tepotinib FDA EU

    Participants with MET alterations, namely METex14 skipping alterations in plasma and/or tissue as determined by the central laboratory or b…

    Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV

17. A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer

    Recruiting Phase 1 Memorial Sloan Kettering Cancer Center Started 2026Primary completion 2029-05 NCT07619339

    tepotinib FDA EUivonescimab

    Patients must have documentation of MET exon 14 skipping present in their cancer using an FDA-approved assay done within a laboratory wit…

    Non-Small Cell Lung Cancer

18. A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors

    Active, not recruiting Phase 1 Avistone Biotechnology Started 2024Primary completion 2027-12 NCT06328439

    ANS014004

    Cohort 1: Subjects must have pathologically confirmed, diagnosed NSCLC with a MET exon 14 jump mutation, with or without other MET alterations, and prior treatment with an approve…

    Locally Advanced or Metastatic Solid Tumors

19. Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours

    Recruiting Phase 1 DeuterOncology Started 2022Primary completion 2027-09 NCT05752552

    DO-2

    To be entered patients must have proven MET exon 14 skipping mutation, determined by local next generation sequencing (NGS), whole exome sequ…

    Adult Solid Tumor, Advanced Solid Tumor, Refractory Tumor, Non-small Cell Lung Cancer

20. Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

    Active, not recruiting Phase 1 Bristol Myers Squibb Started 2019Primary completion 2024-01 NCT03993873

    elzovantinib

    Histological or cytological confirmation of advanced/metastatic MET exon 14 skipping mutation (METΔex14) NSCLC, MET amplified NSCLC, or MET amplified gastric cancers…

    Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations

21. Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

    Active, not recruiting Phase 1 Johnson & Johnson Started 2016Primary completion 2026-12 NCT02609776

    amivantamablazertinibcarboplatinpemetrexed

    …-resistant mutations such as Exon 20 insertion (Cohort C, D and MET-1) or activating cMet Exon 14 skipping mutation (Cohort MET-2).

    Non-Small-Cell Lung Cancer

22. Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

    Recruiting Phase 3 ImmunityBio Started 2025Primary completion 2028-09 NCT06745908

    N-803tislelizumabdocetaxelPrior failed checkpoint inhibitor

    …ase (NTRK), B rapidly accelerated fibrosarcoma (BRAF), mesenchymal epithelial transition (MET) exon 14 skipping, rearranged during transfection (RET), Kirsten Rat sarcoma (KRAS) and HER2.

    Broad match: MET exon 14 skippingNSCLC Stage IV

23. Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

    Active, not recruiting Phase 3 Daiichi Sankyo Started 2020Primary completion 2024-05 NCT04656652

    datopotamab deruxtecandocetaxel

    …ave one or more documented actionable genomic alteration(s): EGFR, ALK, ROS1, NTRK, BRAF, MET exon 14 skipping, or RET.

    Broad match: MET exon 14 skippingNon-small Cell Lung Cancer

24. Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver Mutations

    Not yet recruiting Phase 2 Shanghai Zhongshan Hospital Started 2026Primary completion 2030-06 NCT07829744

    Documented EGFR exon 20 insertion, ALK fusion, ROS1 fusion, MET exon 14 skipping alteration, RET fusion, or KRAS G12C mutation.

    Broad match: MET exon 14 skippingLung Cancer (NSCLC)

25. Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

    Not yet recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai Started 2024Primary completion 2029-11 NCT06644313

    vebreltinib

    … gene testing confirmed MET alterations, which include the following two types: Cohort 1: MET exon 14 skipping mutations (NGS results from tissue or blood samples certified by CLIA or CAP-app…

    Broad match: MET exon 14 skippingStatus may be outdated, last updated 2024-10-16Potentially Resectable MET-altered Non-Small Cell Lung Cancer

26. A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma

    Recruiting Phase 2 Lantern Pharma Started 2023Primary completion 2026-12 NCT05456256

    LP-300pemetrexedcarboplatin

    …ng with specific actionable genomic alterations (e.g., mesenchymal epithelial transition (MET) exon14 skipping mutations, anaplastic lymphoma kinase (ALK), epidermal growth factor receptor (E…

    Broad match: MET exon 14 skippingAdenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

27. Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

    Recruiting Phase 2 Guangdong Provincial People's Hospital Started 2023Primary completion 2024-12 NCT05800340

    toripalimabnab-paclitaxelpemetrexedcarboplatin

    …onfirmed driver mutations), ERBB2 exon20 insertion, MET amplification (FISH confirmed) or exon 14 skipping.

    Broad match: MET exon 14 skippingStatus may be outdated, last updated 2023-04-05Non-Small Cell Lung Cancer, RET Driver Mutation, BRAF V600 Mutation, Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation

28. A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)

    Active, not recruiting Phase 1/2 AstraZeneca Started 2022Primary completion 2023-11 NCT05460273

    datopotamab deruxtecan

    …ted positive test results for one or more actionable genomic alteration: EGFR, ALK, ROS1, METex14 skipping, RET or other AGAs with approved therapies

    Broad match: MET exon 14 skippingCarcinoma, Non-Small-Cell Lung, Triple Negative Breast Cancer

29. RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

    Recruiting Phase 2 Masonic Cancer Center, University of Minnesota Started 2022Primary completion 2028-01 NCT04105270

    Oral Restorative Microbiota Therapy (RMT) Capsulesdurvalumabcisplatinpemetrexedcarboplatin

    BRAF, RET, NTRK, MET ex 14 splice site mutation

    Broad match: MET exon 14 skippingAdenocarcinoma of Lung, Lung Cancer

30. Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

    Active, not recruiting Phase 2 Li Zhang, MD Started 2022Primary completion 2025-11 NCT05003037

    surufatinibtoripalimabpemetrexedcarboplatincisplatin

    BRAF mutation, ERBB2 (HER2) amplification/mutation, MET amplification, MET exon 14 skipping mutation, and NTRK fusion.

    Broad match: MET exon 14 skippingNon Small Cell Lung Cancer

31. Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

    Active, not recruiting Phase 2 SWOG Cancer Research Network Started 2020Primary completion 2026-12 NCT04268550

    selpercatinib

    …90M, ALK gene fusion, ROS1 gene fusion, KRAS activating mutation, BRAF V600E mutation and MET exon 14 skipping mutation or high-level amplification and expression

    Broad match: MET exon 14 skippingRecurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8

32. A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors

    Recruiting Phase 1 CSPC Started 2024Primary completion 2026-10 NCT07110883

    SYS6023

    …ophic Tyrosine Receptor Kinase (RET) rearrangement, HER2 mutation, MET Proto-Oncogene（Met）exon14 skipping mutation, Met amplification, KRAS Proto-Oncogene, GTPase G12C（KRAS G12c） mutation status …

    Broad match: MET exon 14 skippingAdvanced Solid Tumor

33. To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors

    Recruiting Phase 1 Jiangsu Alphamab Biopharmaceuticals Started 2024Primary completion 2026-05 NCT06592417

    JSKN016 injection

    EGFR, ALK, ROS1, NTRK, BRAF V600, MET exon 14, RET, KRAS G12C, or HER2;

    Broad match: MET exon 14 skippingStatus may be outdated, last updated 2024-09-19Advanced Malignant Solid Tumor

No trials match these filters.